Tagged with S

China Dr Ben Zhao, Chief Executive Officer and co-founder of Haichang Biotechnology (HCBio, Haichang), represents a new paradigm in pharmaceutical innovation, bridging regulatory expertise with entrepreneurial vision. Having transitioned from a distinguished career at the FDA to establishing one of the most promising lipid nanoparticle delivery platforms in the industry, he…

USA The latest stories from healthcare and the life sciences in the US. The FDA names Stanford’s George Tidmarsh as the new head of CDER; AstraZeneca commits USD 50 billion to new US manufacturing and R&D projects; Moderna cancels its planned mRNA facility in Japan; Sarepta refuses to halt Elevidys shipments…

Puerto Rico In cell and gene therapy, where R&D and manufacturing are inseparable, Puerto Rico’s strong biopharma base makes it an attractive option for CGT companies.   The first mover in this space is CytoImmune. Founded in 2017 by a cadre of Big Pharma veterans and established in Puerto Rico in 2020,…

Puerto Rico Despite being a small island in the Caribbean, measuring just 100 by 35 miles, Puerto Rico has long punched above its weight as an industrial powerhouse. Already a leading producer of everything from blockbuster medicines to high-tech medical devices, how has it got to this point and what comes next?…

Puerto Rico Spending almost 30 years working for a single company is almost unheard of in today’s life science industry, where executives chop and change between firms with bewildering frequency.   However, in CooperVision – one of the world’s leading soft contact lens manufacturers with Puerto Rico at its beating heart –…

Puerto Rico The largest pharmaceutical hub in the Americas, Puerto Rico currently exports to 120 countries, accounting for nearly USD 53 billion in weekly biopharma shipments. Remarkably, this small Caribbean island out-exports all individual US states, shipping out over twice as much as second-placed Indiana. The life sciences industry is central to this…

Puerto Rico Long celebrated for its world-class pharmaceutical and medical device manufacturing, Puerto Rico is now leveraging this strong foundation to nurture a new era of research and development. Rather than shifting away from production, the island is integrating R&D directly into its manufacturing operations — from pilot plants and small-scale prototyping…

Puerto Rico Can Puerto Rico capitalise on the Trump administration’s “make in America” push?   President Donald Trump wants to bring manufacturing back to America. The last 40 years of globalisation and free trade saw huge chunks of the US supply chain for all kinds of goods, including essential medicines and medical…

Puerto Rico With over 80,000 people directly and indirectly employed in Puerto Rico’s biosciences sector, the island relies heavily on a skilled and stable workforce to maintain its competitive edge. But it faces a tough talent landscape: the median age of the local workforce is rising, and post-hurricane migration, combined with global…

Switzerland Urs Indermühle sees 2025 shaped by three big shifts and two urgent risks: R&D is now mostly sourced externally (just 35 percent developed in‑house), forcing pharma to master licensing and ecosystem partnerships; Asia, especially China, has become a serious innovation hub, making global IP and footprint strategies a priority; and…

France Serge Picaud, the Executive Director of the Paris Vision Institute outlines a bold vision to transform ophthalmology through cutting-edge research and innovation. From pioneering the first successful optogenetic vision restoration to advancing therapies for AMD, myopia, and diabetic retinopathy, the institute blends academic excellence with commercial impact supported by 15…

Mexico Pharmaceutical innovators are sounding the alarm on Mexico’s healthcare reforms, despite the government’s bold claims. At industry group AMIIF’s 75th anniversary, Health Secretary David Kershenobich hailed the Sheinbaum administration’s investments and regulatory shake‑up as game-changing. But pharma leaders argue that real-world access remains elusive, with one industry veteran warning it…